Cargando…

New oral anticoagulants: discussion on monitoring and adherence should start now!

New oral anticoagulants (NOACs) have been introduced to improve anticoagulant therapy worldwide, but safe implementation may require additional measures. First, optimization of dose adjustment based on therapeutic levels of the drug may be more appropriate than fixed dose therapy. The development an...

Descripción completa

Detalles Bibliográficos
Autor principal: ten Cate, Hugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716685/
https://www.ncbi.nlm.nih.gov/pubmed/23809888
http://dx.doi.org/10.1186/1477-9560-11-8
_version_ 1782277575789248512
author ten Cate, Hugo
author_facet ten Cate, Hugo
author_sort ten Cate, Hugo
collection PubMed
description New oral anticoagulants (NOACs) have been introduced to improve anticoagulant therapy worldwide, but safe implementation may require additional measures. First, optimization of dose adjustment based on therapeutic levels of the drug may be more appropriate than fixed dose therapy. The development and implementation in quantitative laboratory assays will enable further dose optimization. Second, non-adherence to medication is a potential threat to the safe use of NOACs. Since cardiovascular medication may not be optimally used in about 50% of patients, procedures to improve adherence are imperative, also for NOAC therapy and in particular in elderly patients.
format Online
Article
Text
id pubmed-3716685
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37166852013-07-20 New oral anticoagulants: discussion on monitoring and adherence should start now! ten Cate, Hugo Thromb J Editorial New oral anticoagulants (NOACs) have been introduced to improve anticoagulant therapy worldwide, but safe implementation may require additional measures. First, optimization of dose adjustment based on therapeutic levels of the drug may be more appropriate than fixed dose therapy. The development and implementation in quantitative laboratory assays will enable further dose optimization. Second, non-adherence to medication is a potential threat to the safe use of NOACs. Since cardiovascular medication may not be optimally used in about 50% of patients, procedures to improve adherence are imperative, also for NOAC therapy and in particular in elderly patients. BioMed Central 2013-06-28 /pmc/articles/PMC3716685/ /pubmed/23809888 http://dx.doi.org/10.1186/1477-9560-11-8 Text en Copyright © 2013 ten Cate; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Editorial
ten Cate, Hugo
New oral anticoagulants: discussion on monitoring and adherence should start now!
title New oral anticoagulants: discussion on monitoring and adherence should start now!
title_full New oral anticoagulants: discussion on monitoring and adherence should start now!
title_fullStr New oral anticoagulants: discussion on monitoring and adherence should start now!
title_full_unstemmed New oral anticoagulants: discussion on monitoring and adherence should start now!
title_short New oral anticoagulants: discussion on monitoring and adherence should start now!
title_sort new oral anticoagulants: discussion on monitoring and adherence should start now!
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716685/
https://www.ncbi.nlm.nih.gov/pubmed/23809888
http://dx.doi.org/10.1186/1477-9560-11-8
work_keys_str_mv AT tencatehugo neworalanticoagulantsdiscussiononmonitoringandadherenceshouldstartnow